Haemonetics will shell out up to 185 million euros ($216 million) to acquire Vivasure Medical, a Galway, Ireland-based medtech that makes arterial closure devices.

Riverwater Partners, an investment management company, released its “Sustainable Value Strategy” Q4 2025 investor letter. A ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. The popular research ...

The ELITE arterial study demonstrated ease of use for Vivasure's PerQseal Elite with no need for pre-close.

We believe that the stock price of Haemonetics (NYSE: HAE), best known for its blood and plasma supplies and services, is undervalued at current levels of $63. HAE stock is down 27% from the levels of ...

Analysts have recently evaluated Haemonetics and provided 12-month price targets. The average target is $87.45, accompanied ...

Investors may be wondering whether Haemonetics at around US$74 is offering value right now, or whether the market is still undecided about its future potential. The stock has been quite mixed lately, ...

Why Haemonetics’ Price Target Just Nudged Higher Haemonetics’ fair value estimate has been nudged higher from about US$90.20 ...

BOSTON, Oct. 6, 2021 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish second quarter fiscal year 2022 financial results at 6:00 am EST on Tuesday, ...

Orchestra BioMed (Nasdaq:OBIO) expects to receive up to $21 million in cash as a result of Haemonetics' recent.

BOSTON, Nov. 6, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its second quarter fiscal year 2026, which ended September 27, 2025, are available on the ...

BOSTON, June 18, 2024 /PRNewswire/ -- Haemonetics Corporation (HAE), a global medical technology company focused on delivering innovative solutions to drive better patient outcomes, has launched a ...